Health & pharma
Developments in this theme
Latest across this theme
The NHS warns that UV rays from sunbeds increase the risk of developing skin cancer.
Advertising watchdog requires sunbed firms to not downplay cancer risk
The NHS warns that UV rays from sunbeds increase the risk of developing skin cancer.
The FDA in the United States identified a possible increase in the risk of rare eye disease for the Risco de perda de visão brand of weight-loss pens.
FDA adds rare vision-loss warning to GLP-1 drugs
The FDA is warning that GLP-1 drugs carry a potential risk for an eye condition
FDA requires warning labels on Ozempic and Wegovy due to risk of permanent vision loss
Bayer received FDA approval for its new stroke medication Sunharbo in the United States.
The FDA requires all GLP-1 weight-loss drugs on the U.S. market to warn of a potential increased risk of an eye stroke.
Bayer's SUNHARBO (asundexian) received FDA approval to reduce the risk of stroke in adults with recent non-cardioembolic ischemic stroke or high-risk transient ischemic attack.
Bayer received FDA approval for Sunharbo, a drug that reduces the risk of stroke in patients with non-cardioembolic ischemic stroke or high-risk transient ischemic attack.
FDA orders new vision loss warning for Ozempic and other GLP-1s
FDA adds rare vision-loss warning to GLP-1 drugs
The FDA ordered GLP-1 medication makers to add a warning about increased risk of vision loss on their drug labels.
FDA requires GLP-1 drugmakers to update product labels to warn of a rare eye condition that could lead to blindness.
Eli Lilly's weight-loss pill shows sleep apnea benefits
Eli Lilly reduced the number of nighttime sleep apnea cases significantly in a new clinical trial for its oral medication.
FDA adds warning label to weight-loss drugs for eye condition
Lilly is seeking approval for its obesity medication in obstructive sleep apnea following a positive Phase 3 trial
Lilly's Obesity Pill Foundayo helps control sleep apnea in a study